AMOYTOP(688278)2024-04-16 07:36Group 1: Product Information - The product Paigebin has been included in the National Medical Insurance Directory (Category B) [3] - The reimbursement rate for Paigebin varies by region due to different local medical insurance policies [3] - There is no significant seasonal sales characteristic for Paigebin [4] Group 2: Sales and Market Insights - The proportion of Paigebin sales that go through medical insurance is difficult to quantify [4] - The number of patients using Paigebin is gradually increasing as scientific evidence accumulates [4] - The exclusive promotion and sales rights of Peijin in mainland China have been granted to Jiangsu Fosun [4] Group 3: Future Expectations - The sales expense ratio is expected to continue decreasing as sales scale increases [5] - The company is awaiting approval for the clinical cure indication for chronic hepatitis B, which is currently under review by the National Medical Products Administration [4] - Future coverage of Paigebin is anticipated to rise as more research supports its efficacy [5] Group 4: Communication and Disclosure - The company ensured that all communications during the performance briefing were conducted in accordance with its information disclosure management system [5] - No undisclosed significant information was leaked during the investor relations activity [5]